EffRx’s business strategy is focused on successfully shaping the late development and launch of therapeutics for patients with musculoskeletal, genitourinary and rare diseases. The business model is centred around providing superior clinical and commercial value propositions for physicians, payers and patients.
Our vision is to be the preferred and dedicated partner in Europe for the late clinical development, approval and valorisation of emerging biopharmaceuticals.
We have a very effective team with proven cross-functional competences in Clinical Development, Medical Affairs, Regulatory Affairs, Market Access, Marketing, Brand & Launch Management, Business Development & Alliance Management, Quality Management, Operations & Supply Chain.
EffRx pro-actively seeks in-licensing opportunities for Europe in the therapeutic areas of its primary interest and for rare diseases, where EffRx has received an orphan drug designation (ODD) from FDA for EX404.